Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (GILD)
NASDAQ:GILD
Total Valuation
Gilead Sciences has a market cap or net worth of $131.74B. The enterprise value is $131.96B.
Market Cap$131.74B
Enterprise Value$131.96B
Share Statistics
Gilead Sciences has 1.25B shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1.25B
Owned by Insiders0.09%
Owned by Instutions0.52%
Financial Efficiency
Gilead Sciences’s return on equity (ROE) is 0.02 and return on invested capital (ROIC) is 2.36%.
Return on Equity (ROE)2.48%
Return on Assets (ROA)0.81%
Return on Invested Capital (ROIC)2.36%
Return on Capital Employed (ROCE)3.54%
Revenue Per Employee$1,633,465.909
Profits Per Employee$27,272.727
Employee Count17,600
Asset Turnover0.49
Inventory Turnover3.66
Valuation Ratios
The current PE Ratio of Gilead Sciences is 239.97. Gilead Sciences’s PEG ratio is -2.62.
PE Ratio239.97
PS Ratio4.01
PB Ratio5.96
Price to Fair Value5.96
Price to FCF11.18
Price to Operating Cash Flow10.64
PEG Ratio-2.62
Income Statement
In the last 12 months, Gilead Sciences had revenue of $28.75B and earned $480.00M in profits. Earnings per share was $0.38.
Revenue$28.75B
Gross Profit$22.50B
Operating Income$8.33B
Pretax Income$691.00M
Net Income$480.00M
EBITDA4.43B
Earnings Per Share (EPS)0.38
Cash Flow
In the last 12 months, operating cash flow was $10.83B and capital expenditures -$376.00M, giving a free cash flow of $10.45B billion.
Operating Cash Flow$10.83B
Free Cash Flow$10.45B
Free Cash Flow per Share$8.38
Dividends & Yields
Gilead Sciences pays an annual dividend of $0.79, resulting in a dividend yield of 2.93%
Dividend Per Share$0.79
Dividend Yield2.93%
Payout Ratio67.18%
Free Cash Flow Yield8.95%
Earnings Yield0.42%
Stock Price Statistics
Beta0.38
52-Week Price Change63.93%
50-Day Moving Average108.15
200-Day Moving Average89.65
Relative Strength Index (RSI)43.75
Average Volume (3m)10.64M
Important Dates
Gilead Sciences upcoming earnings date is Apr 24, 2025, After Close.
Last Earnings DateFeb 11, 2025
Next Earnings DateApr 24, 2025
Ex-Dividend DateMar 14, 2025
Financial Position
Gilead Sciences as a current ratio of 1.60, with Debt / Equity ratio of 0.16
Current Ratio1.60
Quick Ratio1.45
Debt to Market Cap0.03
Net Debt to EBITDA-4.14
Interest Coverage Ratio1.70
Taxes
In the past 12 months, Gilead Sciences has paid $211.00M in taxes.
Income Tax$211.00M
Effective Tax Rate30.58%
Enterprise Valuation
Gilead Sciences EV to EBITDA ratio is 65.17, with an EV/FCF ratio of 10.51.
EV to Sales3.77
EV to EBITDA65.17
EV to Free Cash Flow10.51
EV to Operating Cash Flow10.00
Balance Sheet
Gilead Sciences has $9.99B in cash and marketable securities with $26.71B in debt, giving a net cash position of $16.72B billion.
Cash & Marketable Securities$9.99B
Total Debt$26.71B
Net Cash$16.72B
Net Cash Per Share$13.41
Tangible Book Value Per Share-$7.23
Margins
Gross margin is 78.26%, with operating margin of 5.78%, and net profit margin of 1.67%.
Gross Margin78.26%
Operating Margin5.78%
Pretax Margin2.40%
Net Profit Margin1.67%
EBITDA Margin5.78%
EBIT Margin5.80%
Analyst Forecast
The average price target for Gilead Sciences is $115.56, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$115.56
Price Target Upside10.18%
Analyst ConsensusModerate Buy
Analyst Count23
Revenue Growth Forecast6.16%
EPS Growth Forecast-91.54%